

Elizabeth W Loder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7899628/publications.pdf>

Version: 2024-02-01

107
papers

46,188
citations

94433

37
h-index

49909

87
g-index

111
all docs

111
docs citations

111
times ranked

28867
citing authors

#	ARTICLE	IF	CITATIONS
1	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Journal of Medical Economics, 2022, 25, 1-7.	2.1	9
2	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ, The, 2022, 376, e067975.	6.0	141
3	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Pharmacoeconomics, 2022, 40, 601-609.	3.3	39
4	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value in Health, 2022, 25, 10-31.	0.3	251
5	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Public Health, 2022, 22, 179.	2.9	7
6	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Journal of Managed Care & Specialty Pharmacy, 2022, , 1-10.	0.9	0
7	Equal Pay for Women Neurologists. Neurology, 2022, 98, 347-348.	1.1	0
8	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Health Services Research, 2022, 22, 114.	2.2	5
9	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. International Journal of Technology Assessment in Health Care, 2022, 38, e13.	0.5	78
10	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value in Health, 2022, 25, 3-9.	0.3	254
11	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Medicine, 2022, 20, 23.	5.5	73
12	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Applied Health Economics and Health Policy, 2022, 20, 213.	2.1	12
13	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. European Journal of Health Economics, 2022, 23, 1309-1317.	2.8	9
14	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 146-155.	0.9	3
15	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Clinical Therapeutics, 2022, 44, 158-168.	2.5	22
16	Guidance relevant to the reporting of health equity in observational research: a scoping review protocol. BMJ Open, 2022, 12, e056875.	1.9	5
17	Identification of work accommodations and interventions associated with work productivity in adults with migraine: A scoping review. Cephalalgia, 2021, 41, 760-773.	3.9	13
18	Effectiveness of Mindfulness Meditation vs Headache Education for Adults With Migraine. JAMA Internal Medicine, 2021, 181, 317.	5.1	87

#	ARTICLE	IF	CITATIONS
19	The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. <i>Headache</i> , 2021, 61, 60-68.	3.9	119
20	PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. <i>BMJ</i> , The, 2021, 372, n160.	6.0	3,413
21	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. <i>BMJ</i> , The, 2021, 372, n71.	6.0	26,066
22	The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. <i>PLoS Medicine</i> , 2021, 18, e1003583.	8.4	1,340
23	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. <i>Systematic Reviews</i> , 2021, 10, 89.	5.3	3,624
24	The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. <i>International Journal of Surgery</i> , 2021, 88, 105906.	2.7	3,487
25	Development of a checklist to detect errors in meta-analyses in systematic reviews of interventions: study protocol. <i>F1000Research</i> , 2021, 10, 455.	1.6	2
26	The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2021, 134, 178-189.	5.0	995
27	Declaraci3n PRISMA 2020: una gu3a actualizada para la publicaci3n de revisiones sistem3ticas. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 790-799.	0.6	333
28	Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. <i>BMJ</i> , The, 2021, 375, n2233.	6.0	408
29	Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1614.	7.4	829
30	Pravila PRISMA 2020.. <i>Medicina Fluminensis</i> , 2021, 57, 444-465.	0.3	50
31	Medication overuse headache: The trouble with prevalence estimates. <i>Cephalalgia</i> , 2020, 40, 3-5.	3.9	5
32	Ten Eleven Things Not to Say to Healthcare Professionals During the Coronavirus Disease 2019 Pandemic. <i>Headache</i> , 2020, 60, 1837-1845.	3.9	5
33	Real-world effectiveness and tolerability of erenumab: A retrospective cohort study. <i>Cephalalgia</i> , 2020, 40, 1511-1522.	3.9	61
34	Awareness, usage and perceptions of authorship guidelines: an international survey of biomedical authors. <i>BMJ Open</i> , 2020, 10, e036899.	1.9	23
35	Disentangling placebo effects in the treatment of migraine. <i>Nature Reviews Neurology</i> , 2020, 16, 657-658.	10.1	4
36	Ten (No, Make that 11) Ways the Migraine Mavens Have Changed the Conversation About Sexism in Medicine. <i>Headache</i> , 2020, 60, 1042-1046.	3.9	0

#	ARTICLE	IF	CITATIONS
37	Addressing the Crisis of Diagnosis and Management of Migraine in Primary Care: A Summary of the American Headache Society FrontLine Primary Care Advisory Board. Headache, 2020, 60, 1000-1004.	3.9	9
38	Workforce Gap Analysis in the Field of Headache Medicine in the United States. Headache, 2020, 60, 478-481.	3.9	19
39	Characteristics of Neuropsychiatric Mobile Health Trials: Cross-Sectional Analysis of Studies Registered on ClinicalTrials.gov. JMIR MHealth and UHealth, 2020, 8, e16180.	3.7	1
40	Underrepresentation of Women Among Authors of Invited Commentaries in Medical Journals—Where Are the Female Editorialists?. JAMA Network Open, 2019, 2, e1913665.	5.9	19
41	Ten Eleven Things Not to Say to Your Female Colleagues. Headache, 2019, 59, 1846-1854.	3.9	12
42	Further Questioning of the Significance of the Gepants: A Response. Headache, 2019, 59, 1831-1831.	3.9	0
43	Time—™s up for he and him as the default pronouns for doctors. BMJ, The, 2019, 367, l6565.	6.0	0
44	Potential Benefits of Migraine—™What Is It Good For?. JAMA Neurology, 2019, 76, 250.	9.0	2
45	The Emperor—™s New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?. Headache, 2019, 59, 113-117.	3.9	45
46	Calcitonin Gene-Related Peptide Monoclonal Antibody Treatments for Migraine. JAMA Internal Medicine, 2019, 179, 421.	5.1	6
47	Consideration of Costs and Open-Label Studies of Erenumab—™Reply. JAMA Neurology, 2019, 76, 236.	9.0	3
48	Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome. JAMA Neurology, 2018, 75, 566.	9.0	64
49	The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies. Headache, 2018, 58, 496-505.	3.9	330
50	Risk of Stroke Associated With Use of Estrogen Containing Contraceptives in Women With Migraine: A Systematic Review. Headache, 2018, 58, 5-21.	3.9	65
51	Biomedical authors—™ awareness of publication ethics: an international survey. BMJ Open, 2018, 8, e021282.	1.9	12
52	Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process. Headache, 2018, 58, 1639-1657.	3.9	9
53	Who Should Try New Antibody Treatments for Migraine?. JAMA Neurology, 2018, 75, 1039.	9.0	24
54	Monoclonal Antibodies for Migraine Prevention. JAMA - Journal of the American Medical Association, 2018, 319, 1985.	7.4	14

#	ARTICLE	IF	CITATIONS
55	Migraine Pain Location and Measures of Healthcare Use and Distress: An Observational Study. Pain Research and Management, 2018, 2018, 1-11.	1.8	8
56	Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018. Headache, 2018, 58, 218-229.	3.9	41
57	Variation in Prescription Drug Coverage for Triptans: Analysis of Insurance Formularies. Headache, 2017, 57, 1243-1251.	3.9	4
58	The comorbidity burden of patients with cluster headache: a population-based study. Journal of Headache and Pain, 2017, 18, 76.	6.0	21
59	Medication overuse headache. Neurology, 2017, 89, 1296-1304.	1.1	58
60	Validity of cluster headache diagnoses in an electronic health record data repository. Headache, 2016, 56, 1132-1136.	3.9	8
61	A migraine management training program for primary care providers: An overview of a survey and pilot study findings, lessons learned, and considerations for further research. Headache, 2016, 56, 725-740.	3.9	38
62	Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache, 2016, 56, 821-834.	3.9	160
63	Amitriptyline Dose and Treatment Outcomes in Specialty Headache Practice: A Retrospective Cohort Study. Headache, 2016, 56, 1626-1634.	3.9	23
64	Migraine diagnosis and treatment: A knowledge and needs assessment among primary care providers. Cephalalgia, 2016, 36, 358-370.	3.9	45
65	Headache Rounds: Sudden, Transient Neurologic Symptoms in a Woman With Migraine. Headache, 2015, 55, 1274-1282.	3.9	2
66	The Prevalence and Burden of Migraine and Severe Headache in the <sc>United States</sc>: Updated Statistics From Government Health Surveillance Studies. Headache, 2015, 55, 21-34.	3.9	405
67	The Prevalence, Burden, and Treatment of Severe, Frequent, and Migraine Headaches in <sc>US</sc> Minority Populations: Statistics From National Survey Studies. Headache, 2015, 55, 214-228.	3.9	82
68	Registration status and outcome reporting of trials published in core headache medicine journals. Neurology, 2015, 85, 1789-1794.	1.1	23
69	Adding NSAIDs to triptans: Could less be more?. Cephalalgia, 2014, 34, 407-408.	3.9	4
70	Consolidated Health Economic Evaluation Reporting Standards (CHEERS)â€”Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health, 2013, 16, 231-250.	0.3	1,657
71	The Prevalence, Impact, and Treatment of Migraine and Severe Headaches in the <sc>United States</sc>: A Review of Statistics From National Surveillance Studies. Headache, 2013, 53, 427-436.	3.9	319
72	Choosing Wisely in Headache Medicine: The <sc>American</sc> Headache Society's List of Five Things Physicians and Patients Should Question. Headache, 2013, 53, 1651-1659.	3.9	150

#	ARTICLE	IF	CITATIONS
73	Evaluation for Secondary Causes of Headache: The Role of Blood and Urine Testing. Headache, 2011, 51, 338-345.	3.9	19
74	The approach to the difficult patient. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 233-238.	1.8	2
75	Triptan Therapy in Migraine. New England Journal of Medicine, 2010, 363, 63-70.	27.0	178
76	Prophylaxis: Headaches That Never Happen. Headache, 2008, 48, 694-696.	3.9	6
77	Tension-type headache. BMJ: British Medical Journal, 2008, 336, 88-92.	2.3	52
78	Hormonal Management of Migraine Associated With Menses and the Menopause: A Clinical Review.. Headache, 2007, 47, 329-340.	3.9	38
79	Menstrual Migraine: Pathophysiology, Diagnosis, and Impact. Headache, 2006, 46, S55-S60.	3.9	18
80	Conclusion: How primary care physicians can help their patients with migraine. The American Journal of Medicine: Supplement, 2005, 118, 45-46.	1.6	0
81	Headache as a side effect of combination estrogen-progestin oral contraceptives: A systematic review. American Journal of Obstetrics and Gynecology, 2005, 193, 636-649.	1.3	81
82	General Principles of Migraine Management: The Changing Role of Prevention. Headache, 2005, 45, S33-S47.	3.9	61
83	Pain-free rates with zolmitriptan 2.5â€‰mg ODT in the acute treatment of migraine: results of a large double-blind placebo-controlled trial. Current Medical Research and Opinion, 2005, 21, 381-389.	1.9	35
84	Headache Attributed to Psychiatric Disorder: A Case Series. Psychosomatics, 2005, 46, 326-333.	2.5	9
85	Part II: Clinical efficacy and tolerability of zolmitriptan orally disintegrating tablet in the acute treatment of migraine. Current Medical Research and Opinion, 2005, 21, S8-S12.	1.9	7
86	Fixed Drug Combinations for the Acute Treatment of Migraine. CNS Drugs, 2005, 19, 769-784.	5.9	23
87	Offâ€Label Prescribing of Drugs in Specialty Headache Practice. Headache, 2004, 44, 636-641.	3.9	29
88	Migraine diagnosis and treatment. Primary Care - Clinics in Office Practice, 2004, 31, 277-292.	1.6	2
89	Who Will Prescribe? A Proposal for Specialized Opioid Management Clinics. Pain Practice, 2003, 3, 218-221.	1.9	0
90	Safety of Sumatriptan in Pregnancy. CNS Drugs, 2003, 17, 1-7.	5.9	62

#	ARTICLE	IF	CITATIONS
91	Use of Botulinum Toxins for Chronic Headaches: A Focused Review. Clinical Journal of Pain, 2002, 18, S169-S176.	1.9	47
92	Naratriptan in the Prophylaxis of Cluster Headache. Headache, 2002, 42, 56-57.	3.9	28
93	Volume and Nature of Telephone Calls in a Specialty Headache Practice. Headache, 2002, 42, 883-887.	3.9	16
94	A Pilot Study of Pain and Attitudes Toward Pain in a Rehabilitation Population. Pain Medicine, 2002, 3, 333-338.	1.9	3
95	Review: several drugs, especially triptans, are effective for pain relief in acute migraine. ACP Journal Club, 2002, 137, 103.	0.1	0
96	Review: Several drugs, especially triptans, are effective for pain relief in acute migraine. ACP Journal Club, 2002, 137, 103.	0.1	0
97	Mistaking primary headache for another condition. , 0, , 20-37.		0
98	When historical or examination findings are missed or misinterpreted. , 0, , 84-99.		0
99	Medicolegal pitfalls in headache management. , 0, , 175-185.		0
100	Missing dangerous causes of headache. , 0, , 38-53.		0
101	Pitfalls in diagnostic testing: imaging and lumbar puncture. , 0, , 54-72.		0
102	Errors in management of acute headache. , 0, , 100-118.		0
103	Pitfalls in diagnostic testing: blood, urine, and other tests. , 0, , 73-83.		0
104	Pitfalls in drug therapy to prevent headaches. , 0, , 119-144.		0
105	Pitfalls in nonpharmacologic treatment of headache. , 0, , 145-161.		0
106	Challenges and special situations in headache management. , 0, , 162-174.		0
107	Confusing one benign headache with another. , 0, , 1-19.		0